Prevalence of lymphedema symptoms across cancer diagnoses and association with depression, pain interference and health-related quality of life
DOI:
https://doi.org/10.2340/1651-226X.2025.42203Keywords:
cancer-related late-effects, cancer survivorship, swelling, heavinessAbstract
Background and purpose: Lymphedema is a debilitating late effect of cancer treatments, yet its prevalence beyond breast cancer remains understudied. This study examined the prevalence of lymphedema symptoms across cancer diagnoses and their association with depression, pain interference, and health-related quality of life (HRQoL).
Patients/Material and methods: This cross-sectional study was conducted at the Department of Oncology, Copenhagen University Hospital, from February to April 2021, as part of a broader investigation into cancer-related late effects. Here, we present data from patients in follow-up who received online lymphedema symptom assesments (swelling, heaviness, or tightness). Utilized questionnaires were the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, the Major Depression Inventory, and the Brief Pain Inventory. Associations between lymphedema symptoms and depression, pain interference, and HRQoL were examined via multiple linear regression.
Results: Of 1,901 patients in follow-up who received the lymphedema symptom items, 1,296 responded. Most participants had breast cancer (48%), followed by testicular (17%), gynecological (16%), and head/neck cancer (11%). One-third (n = 397) reported lymphedema symptoms, with 38% (n = 152) reporting moderate/severe symptoms. The highest symptom prevalence was seen in gynecological cancer (59%), followed by head/neck (41%), breast (21%), and testicular cancer (19%). Participants with moderate/severe lymphedema symptoms were significantly more likely to report higher depression and pain interference scores and lower HRQoL scores compared to those with no/mild symptoms.
Interpretation: Lymphedema symptoms are highly prevalent among patients who have completed treatment for diverse cancers and associated with higher scores for depression and pain interference, and lower HRQoL
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
https://doi.org/10.3322/caac.21660 DOI: https://doi.org/10.3322/caac.21660
Keast DH, Despatis M, Allen JO, Brassard A. Chronic oedema/lymphoedema: under-recognised and under-treated. Int Wound J. 2015;12(3):328–33.
https://doi.org/10.1111/iwj.12224 DOI: https://doi.org/10.1111/iwj.12224
Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116(22):5138–49.
https://doi.org/10.1002/cncr.25458 DOI: https://doi.org/10.1002/cncr.25458
Consensus document. The diagnosis and treatment of peripheral lymphedema: 2020 Consensus Document of the International Society of Lymphology. Lymphology. 2020;53(1):3–19.
https://doi.org/10.2458/lymph.4649 DOI: https://doi.org/10.2458/lymph.4649
González-Fernández L, Romero-Morales C, Martínez-Pascual B, Río-González A, Cerezo-Téllez E, López-Martín I. Breast cancer survivors suffering from lymphedema: what really do affect to corporeality/body image? A qualitative study. Breast Cancer Res. 2024;26(1):47.
https://doi.org/10.1186/s13058-024-01806-9 DOI: https://doi.org/10.1186/s13058-024-01806-9
Scerri J, Cilia Vincenti S, Galea M, Cefai C, Grech P, Sammut A, et al. Hit by the wave: the experiences of adult males living with lymphoedema. PLoS One. 2024;19(5):e0304577.
https://doi.org/10.1371/journal.pone.0304577 DOI: https://doi.org/10.1371/journal.pone.0304577
Bowman C, Piedalue KA, Baydoun M, Carlson LE. The quality of life and psychosocial implications of cancer-related lower-extremity lymphedema: a systematic review of the literature. J Clin Med. 2020;9(10):14–16.
https://doi.org/10.3390/jcm9103200 DOI: https://doi.org/10.3390/jcm9103200
Carter J, Huang HQ, Armer J, Carlson JW, Lockwood S, Nolte S, et al. GOG 244 – the Lymphedema and Gynecologic cancer (LeG) study: the impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function. Gynecol Oncol. 2021;160(1):244–51.
https://doi.org/10.1016/j.ygyno.2020.10.023 DOI: https://doi.org/10.1016/j.ygyno.2020.10.023
Jeans C, Brown B, Ward EC, Vertigan AE, Pigott AE, Nixon JL, et al. A prospective, longitudinal and exploratory study of head and neck lymphoedema and dysphagia following chemoradiotherapy for head and neck cancer. Dysphagia. 2023;38(4):1059–71.
https://doi.org/10.1007/s00455-022-10526-1 DOI: https://doi.org/10.1007/s00455-022-10526-1
Karaca-Mandic P, Solid CA, Armer JM, Skoracki R, Campione E, Rockson SG. Lymphedema self-care: economic cost savings and opportunities to improve adherence. Cost Eff Resour Alloc. 2023;21(1):47.
https://doi.org/10.1186/s12962-023-00455-7 DOI: https://doi.org/10.1186/s12962-023-00455-7
De Vrieze T, Gebruers N, Nevelsteen I, Tjalma WAA, Thomis S, De Groef A, et al. Breast cancer-related lymphedema and its treatment: how big is the financial impact? Support Care Cancer. 2021;29(7): 3801–13.
https://doi.org/10.1007/s00520-020-05890-3 DOI: https://doi.org/10.1007/s00520-020-05890-3
Rafn BS, Christensen J, Larsen A, Bloomquist K. Prospective surveillance for breast cancer-related arm lymphedema: a systematic review and meta-analysis. J Clin Oncol. 2022;40(9):1009–26.
https://doi.org/10.1200/JCO.21.01681 DOI: https://doi.org/10.1200/JCO.21.01681
Clinckaert A, Callens K, Cooreman A, Bijnens A, Moris L, Van Calster C, et al. The prevalence of lower limb and genital lymphedema after prostate cancer treatment: a systematic review. Cancers (Basel). 2022;14(22):14–15.
https://doi.org/10.3390/cancers14225667 DOI: https://doi.org/10.3390/cancers14225667
Son A, O’Donnell TF, Jr., Izhakoff J, Gaebler JA, Niecko T, Iafrati MA. Lymphedema-associated comorbidities and treatment gap. J Vasc Surg Venous Lymphat Disord. 2019;7(5):724–30.
https://doi.org/10.1016/j.jvsv.2019.02.015 DOI: https://doi.org/10.1016/j.jvsv.2019.02.015
Fayers PM AN, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 scoring manual (3rd edition). European Organisation for Research and Treatment of Cancer; 2001 [cited 2023 Jan 12]. Available from: https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf
Bech P, Timmerby N, Martiny K, Lunde M, Soendergaard S. Psychometric evaluation of the Major Depression Inventory (MDI) as depression severity scale using the LEAD (Longitudinal Expert Assessment of All Data) as index of validity. BMC Psychiatry. 2015;15:190.
https://doi.org/10.1186/s12888-015-0529-3 DOI: https://doi.org/10.1186/s12888-015-0529-3
Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, et al. Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017;158(6):1108–12.
https://doi.org/10.1097/j.pain.0000000000000890 DOI: https://doi.org/10.1097/j.pain.0000000000000890
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
https://doi.org/10.1093/jnci/85.5.365 DOI: https://doi.org/10.1093/jnci/85.5.365
Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1–8.
https://doi.org/10.1016/j.jclinepi.2019.10.003 DOI: https://doi.org/10.1016/j.jclinepi.2019.10.003
Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.
https://doi.org/10.1093/aje/kwq433 DOI: https://doi.org/10.1093/aje/kwq433
DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15.
https://doi.org/10.1016/S1470-2045(13)70076-7 DOI: https://doi.org/10.1016/S1470-2045(13)70076-7
Hayes SC, Janda M, Ward LC, Reul-Hirche H, Steele ML, Carter J, et al. Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecol Oncol. 2017;146(3):623–9.
https://doi.org/10.1016/j.ygyno.2017.06.004 DOI: https://doi.org/10.1016/j.ygyno.2017.06.004
Ridner SH, Dietrich MS, Niermann K, Cmelak A, Mannion K, Murphy B. A prospective study of the lymphedema and fibrosis continuum in patients with head and neck cancer. Lymphat Res Biol. 2016;14(4):198–205.
https://doi.org/10.1089/lrb.2016.0001 DOI: https://doi.org/10.1089/lrb.2016.0001
Letellier ME, Ibrahim M, Towers A, Chaput G. Incidence of lymphedema related to various cancers. Med Oncol. 2024;41(10):245.
https://doi.org/10.1007/s12032-024-02441-2 DOI: https://doi.org/10.1007/s12032-024-02441-2
Mestre S, Vignes S, Malloizel-Delaunay J, Abba S, Villet S, Picolet A, et al. Positive impact of a new compressive garment in patients with genital lymphedema: OLYMPY study. Lymphat Res Biol. 2024;22(2):138–46.
Handberg C, Lomborg K, Nielsen CV, Oliffe JL, Midtgaard J. Understanding male cancer patients’ barriers to participating in cancer rehabilitation. Eur J Cancer Care (Engl). 2015;24(6):801–11.
https://doi.org/10.1111/ecc.12358 DOI: https://doi.org/10.1111/ecc.12358
Worlds Health Organization. The health and well-being of men in the WHO European Region: better health through a gender approach. 2018. Regional Office for Europe, ´ Copenhagen. Available from: https://iris.who.int/handle/10665/329686
Noble‐Jones R, Thomas MJ, Bose P. The Lymphoedema Genitourinary Cancer Questionnaire in urology follow‐up clinics. Int J Urol Nurs. 2019;13(1):5–12.
https://doi.org/10.1111/ijun.12174 DOI: https://doi.org/10.1111/ijun.12174
Lee J, Byun HK, Im SH, Son WJ, Roh YH, Kim YB. Risk factors for lower extremity lymphedema after surgery in cervical and endometrial cancer. J Gynecol Oncol. 2023;34(3):e28.
https://doi.org/10.3802/jgo.2023.34.e28 DOI: https://doi.org/10.3802/jgo.2023.34.e28
Shen A, Lu Q, Fu X, Wei X, Zhang L, Bian J, et al. Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies. Support Care Cancer. 2022;31(1):18.
https://doi.org/10.1007/s00520-022-07508-2 DOI: https://doi.org/10.1007/s00520-022-07508-2
Monteiro AJ, de Labra C, Losa-Iglesias ME, Dias A, Becerro-de-Bengoa-Vallejo R, Silva-Migueis H, et al. Depressive symptoms and their severity in a sample with lymphedema: a case-control investigation. Front Psychiatry. 2023;14:1202940.
https://doi.org/10.3389/fpsyt.2023.1202940 DOI: https://doi.org/10.3389/fpsyt.2023.1202940
Bjerre Trent PK, Nordskar NJ, Wangen KR, Engeskaug MI, Opheim M, Aune G, et al. Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: a population based cross-sectional study. Gynecol Oncol. 2023;175:72–80.
https://doi.org/10.1016/j.ygyno.2023.05.070 DOI: https://doi.org/10.1016/j.ygyno.2023.05.070
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Gitte Sone Larsen, Christoffer Johansen, Annika von Heymann, Bolette Skjødt Rafn
This work is licensed under a Creative Commons Attribution 4.0 International License.
